BridgeBio Oncology Widens Loss as Trial Spending Nearly Doubles
BridgeBio Oncology Therapeutics (BBOT) posted a net loss of $56.5 million for the second quarter, roughly double the year-earlier figure, as spending on its three lead cancer programs accelerated.
BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biotechnology company developing precision therapies for genetically defined cancers, reported a net loss of $56.5 million for the second quarter of 2026, up from $28.4 million a year earlier. The widening loss came as the company ramped up clinical and manufacturing work across its pipeline while absorbing the one-time costs of becoming a standalone public entity.
Research and development expenses rose to $49.2 million from $27.4 million, an increase of about 79.5%, due to higher clinical trial and manufacturing costs for its three lead candidates, BBO-8520, BBO-11818 and BBO-10203. General and administrative expenses climbed more sharply in percentage terms, to $11.0 million from $2.7 million, reflecting the initiation of standalone operations, transaction costs tied to the company's de-SPAC listing, and one-time severance payments to former executives.
Net loss per share widened to $705.20 from $566.46, even as the weighted-average share count grew to 80.1 million from 50.2 million, underscoring how the pace of spending outstripped the dilution from the expanded share base.
The higher spending has begun to draw down the balance sheet. Cash, cash equivalents and marketable securities fell to $344.1 million as of June 30, 2026, from $425.5 million at the end of 2025, a decline of about 19.1%. Total assets dropped to $376.7 million from $448.4 million over the same period, while total liabilities rose to $53.6 million from $37.3 million, an increase of about 43.7%.
The spending increase tracked new activity across BridgeBio Oncology's pipeline. During the quarter the company initiated a combination of BBO-8520 and BBO-10203 in patients with G12C-mutated non-small cell lung cancer, an internal combination strategy not previously disclosed. It also began dosing a combination of BBO-11818 with cetuximab, and after the quarter closed started dosing a second combination pairing BBO-11818 with BBO-10203.
Despite the faster cash burn, BridgeBio Oncology's $344.1 million cash position supports operations into 2028. That guidance implies the company is prepared to fund the expanded combination-trial activity through multiple data readouts without a near-term need to raise additional capital, though the pace of spending growth outstripped revenue-free biotechs' typical burn trajectory and will bear watching in subsequent quarters.